secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-05-11T21:17:22+00:00
Accession:  0001999371-26-010487
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q1 net loss $40.2M; TONMYA launch generates $3.7M revenue with 2,145 prescribers
--------------------------------------------------------------------------------

- Net product revenue $6.9M (TONMYA $3.7M, legacy products $3.2M); net loss $40.2M ($2.93/share).
- Cash $185.5M at Mar 31; raised $22.6M post-quarter via ATM; runway into early Q2 2027.
- TONMYA Q1: 2,145 HCPs prescribed, 3,588 patients initiated, ~5,400 Rx; cumulative 11,016 Rx through May 1.
- Secured GPO agreement covering ~35M commercial lives; Medicaid coverage in 38 states (~55M lives).
- TNX-4800 Phase 2 Lyme prevention study planned for 2027; TNX-102 SL MDD Phase 2 to start mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/0001999371-26-010487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937126010487/tnxp-8k_051126.htm
  HTML page:      https://secwatch.observer/filing/0001999371-26-010487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer